psychedelics-investing Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million
psychedelics-investing Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals
psychedelics-investing Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
psychedelics-investing Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada
psychedelics-investing Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30
psychedelics-investing Stocks2Watch to Host Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30th
psychedelics-investing Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
psychedelics-investing Levitee Labs Publishes First Combined Revenue Figures for September 2021 and October 2021
psychedelics-investing Levitee Labs Signs LOI to Acquire Controlling Interest in a R&D Compounding Pharmacy; Focus to be on Levitee-Branded Products
psychedelics-investing Levitee Labs Announces Gold Sponsorship of Wonderland Psychedelic Conference in Miami
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
